While new combination vaccines could be highly valuable to pediatric immunization programs worldwide, vaccine manufacturers have lacked clear guidance for their development and policy bodies have faced challenges in making informed decisions about their introduction and use. In addition, economic evaluations have not assessed the full array of benefits and risks associated with combination vaccines. As part of a broader effort to identify and prioritize high-potential new routine combination vaccines for children, PATH and the World Health Organization (WHO) researched and identified new approaches to measure the full economic value of combination vaccines. This brief shares a new checklist tool they developed to provide analysts with a way to more clearly, consistently, and comprehensively evaluate these vaccines.